SHR-A2102

SHR-A2102 is an investigational agent whose form is not stated in the registry developed by Shanghai Hengrui Pharmaceutical and Suzhou Suncadia Biopharmaceuticals. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. ClinicalTrials.gov describes the intervention as: SHR-A2102: injection, 80mg/ bottle, intravenous drip. It is the investigational product in 9 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07418749 (A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer), in cervical cancer, non-small-cell lung cancer, head and neck squamous cell carcinoma and bladder & urothelial cancer. The largest, NCT06895928, plans to enrol 400 participants with primary completion expected 2028-12. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.